Ignite Creation Date:
2025-12-25 @ 3:11 AM
Ignite Modification Date:
2026-05-28 @ 9:11 PM
Study NCT ID:
NCT02169505
Status:
TERMINATED
Last Update Posted:
2019-11-27
First Post:
2014-06-11
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
Sponsor:
Organization: